Vilon 20mg – Lys-Glu Research Peptide | Biotech Peptides

Original price was: $65.00.Current price is: $61.00.

Vilon 20mg is a synthetic dipeptide composed of L-lysine and L-glutamic acid, with the reference sequence Lys-Glu (KE). Also known as lysylglutamic acid, Vilon has been investigated in laboratory research involving lymphocyte chromatin, cellular processes, and animal models of aging and tumour development. Biotech Peptides lists this compound for laboratory and analytical research.

Reference molecular information:

  • Listed quantity: 20mg
  • Sequence: H-Lys-Glu-OH
  • Peptide length: 2 amino-acid residues
  • Molecular formula: C₁₁H₂₁N₃O₅
  • Molecular weight: 275.30 g/mol
  • CAS number: 45234-02-4

Explore our research peptide collection for additional laboratory research materials.

For laboratory and analytical research only. Not for human or animal consumption, personal administration, medical treatment, diagnosis, or veterinary application.

SKU: Vilon-20mg Category:
Description

Vilon 20mg – Lys-Glu Research Dipeptide

Vilon 20mg is a synthetic dipeptide consisting of L-lysine followed by L-glutamic acid, represented by the sequence Lys-Glu (KE). Also called lysylglutamic acid, Vilon is one of the short peptide bioregulators investigated in experimental research associated with the thymus, lymphocyte biology, and age-related cellular processes.

Vilon has been examined in cell-culture and animal studies, including research on chromatin organisation in lymphocytes and tumour development in rodent models. These findings provide experimental context for the compound; they do not establish clinical benefits or therapeutic effects in humans.

Biotech Peptides lists Vilon as a 20mg research product for laboratory and analytical use.

Vilon 20mg – Product Information

Property Reference information
Product name Vilon
Listed quantity 20mg
Alternative name Lysylglutamic acid
Short sequence KE
Amino-acid sequence L-Lysine–L-glutamic acid
Condensed sequence H-Lys-Glu-OH
Peptide length 2 residues
Molecular formula C₁₁H₂₁N₃O₅
Molecular weight 275.30 g/mol
CAS number 45234-02-4
Compound class Dipeptide

These values describe the reference chemical identity of Vilon. They do not independently confirm the purity, salt or counterion form, or measured peptide content of the supplied product.

Chemical Identity and Structure

Vilon is a linear dipeptide formed by a peptide bond between two L-amino-acid residues:

  • L-Lysine (Lys, K): The first amino-acid residue.
  • L-Glutamic acid (Glu, E): The second amino-acid residue.

Its sequence is written as Lys-Glu or KE, with the condensed structure represented as H-Lys-Glu-OH. The reference structure has free terminal groups and is not a cyclic peptide or an amidated sequence.

The molecular formula is C₁₁H₂₁N₃O₅, corresponding to an average molecular weight of approximately 275.30 g/mol.

Vilon should also be distinguished from other short peptide bioregulators. Similar research terminology or shared amino-acid residues do not make different peptide sequences chemically interchangeable.

Scientific Research on Vilon

Published studies have investigated Vilon in several experimental contexts. Much of the reported evidence comes from research groups studying short peptide bioregulators, and findings should be interpreted according to the specific compound, model, and experimental conditions.

Lymphocyte Chromatin Research

A 2004 study by Lezhava and colleagues examined Vilon in cultured lymphocytes obtained from older human donors. The researchers reported changes in chromatin organisation, including deheterochromatinisation of certain regions and reactivation of ribosomal gene activity.

The study also reported that Vilon did not induce decondensation of pericentromeric structural heterochromatin. This distinction is important: the reported observations concerned specific chromatin regions and cultured cells, not a demonstrated reversal of biological aging in people.

Read the 2004 study: Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people.

Vilon and Animal Lifespan Research

Khavinson and colleagues published a 2000 study investigating Vilon in female CBA mice. The research examined biological-age-related measures, physical activity, lifespan, and spontaneous neoplasm development.

The authors reported increased physical activity and a reduction in spontaneous lung adenoma incidence in the Vilon-treated animals. This was an animal study and does not demonstrate an anti-aging or anti-cancer effect in humans.

Read the 2000 study: Effect of Vilon on biological age and lifespan in mice.

Research on Chemically Induced Bladder Tumours

A 2001 study by Pliss and colleagues investigated Vilon in rats exposed to N-butyl-N-(4-hydroxybutyl)nitrosamine, a chemical used to induce urinary bladder tumours in experimental models.

The researchers reported tumour development in 56% of Vilon-treated animals compared with 75.5% of controls, alongside reductions in certain early neoplastic changes in the bladder mucosa.

These findings are specific to a chemically induced rat model. They do not establish that Vilon prevents or treats cancer in humans.

Read the 2001 study: Inhibitory effect of peptide Vilon on the development of induced rat urinary bladder tumours.

Vilon and Cyclophosphamide: An Important Experimental Finding

Research has also examined Vilon in combination with cyclophosphamide, an established cytotoxic research compound. In one mouse study, simultaneous administration of Vilon and cyclophosphamide was associated with reduced survival compared with the relevant experimental conditions. The researchers also reported that Vilon abolished cyclophosphamide’s inhibitory effect in rat spleen tissue culture.

This is an important limitation when interpreting the literature. It shows that experimental interactions may be complex and that findings from one research setting should not be generalised to another.

Read the study: Combined effect of Vilon and cyclophosphane on tumor transplants and lymphoid tissue explants in mice and rats of various age.

Research Interpretation and Limitations

Vilon research includes cell-culture experiments, animal studies, and investigations of isolated tissues. These experimental settings are not equivalent to controlled human clinical trials.

In particular:

  • Chromatin observations in cultured lymphocytes do not demonstrate reversal of aging in people.
  • Tumour findings in chemically treated rodents do not establish cancer prevention or treatment in humans.
  • Experimental immune-cell changes do not establish improved immune function or prevention of autoimmune disease.
  • Findings involving Vilon in combination with another compound must be interpreted separately from studies of Vilon alone.

The published evidence provides research context rather than proof of a clinical outcome.

Product Documentation and Batch Information

The listed quantity for this product is 20mg. The molecular formula, sequence, molecular weight, and CAS number above are reference information for Vilon, not batch-specific analytical results.

Manufacturer specifications and batch documentation should be reviewed separately when evaluating a research material. Where available, a certificate of analysis can provide batch-specific information about identity, assay, and analytical testing.

No batch-specific COA, purity percentage, HPLC result, mass-spectrometry result, sterility result, or endotoxin result is established by the reference chemistry presented here.

Frequently Asked Questions

What is Vilon?

Vilon is a short synthetic dipeptide composed of L-lysine and L-glutamic acid. Its sequence is Lys-Glu (KE), and it is also known as lysylglutamic acid.

What is the molecular weight of Vilon?

The reference molecular weight of Vilon is approximately 275.30 g/mol. Its molecular formula is C₁₁H₂₁N₃O₅.

What is the amino-acid sequence of Vilon?

The sequence is L-Lys-L-Glu, commonly written as Lys-Glu or KE. Its condensed notation is H-Lys-Glu-OH.

What has Vilon been studied for?

Published experimental research has examined Vilon in lymphocyte chromatin studies, animal models of aging, and chemically induced tumour models. These findings are preclinical or laboratory-based and should not be interpreted as established human health effects.

Is Vilon the same as other thymic peptide bioregulators?

No. Vilon is specifically the Lys-Glu dipeptide. Other short peptide bioregulators have different amino-acid sequences and chemical identities.

Research Use Only

Vilon 20mg is listed for laboratory and analytical research. Researchers should verify the chemical identity and applicable batch documentation when selecting materials for scientific investigations.

For further information, review the Biotech Peptides laboratory and analytical use policy and shipping policy.

For laboratory and analytical research only. Not for human or animal consumption, personal administration, medical treatment, diagnosis, or veterinary application.

Additional information
BrandBiotech Peptides
Shipping & Delivery